{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-029318","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.463456+00:00","generated_at":"2026-06-04T03:26:59.518497+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OptimizeRx reports preliminary Q4 GAAP net loss of $7.2M, extends audited financials deadline","bullets":["GAAP net loss for Q4 2023 was $7.2M vs $0.3M loss in Q4 2022; FY2023 net loss $20.6M vs $11.4M.","Adjusted EBITDA for Q4 2023 was $5.8M vs $3.9M; FY2023 Adjusted EBITDA $3.6M vs $5.5M.","Recorded $6.7M asset impairment and $2.1M loss on disposal of business in Q4 2023.","Lenders extended deadline for audited FY2023 financial statements to April 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-029318","json":"https://secwatch.observer/filing/0001213900-24-029318.json","markdown":"https://secwatch.observer/filing/0001213900-24-029318.md","text":"https://secwatch.observer/filing/0001213900-24-029318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/ea0203141-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:26:59.518497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f95aedb5744b60a24f2e3ad717892ca046d556a6","claim":"OptimizeRx Corp reported preliminary financial results for the three and twelve months ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, the Company held a conference call to discuss preliminary, unaudited results for the fourth quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"16ebd029031ca7f7708c425cc5c9e8e0678f066e","claim":"OptimizeRx Corp amended Financing Agreement with Blue Torch Finance, LLC valued at Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20 (effective 2024-03-29).","evidence_excerpt":"On March 29, 2024, OptimizeRx Corporation (the “Company”) entered into Amendment No. 1 to the Financing Agreement (the “Amendment”) which amends the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “Financing Agreement”) between the Company, the lenders from time to time party thereto (the “Lenders”) and Blue Torch Finance, LLC, a Delaware limited liability company (“Blue Torch”), as collateral agent and administrative agent for the Lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Blue Torch Finance, LLC"},{"label":"Value","value":"Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20"},{"label":"Effective","value":"2024-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}